Artivion (NYSE:AORT) Shares Gap Down After Analyst Downgrade

Artivion, Inc. (NYSE:AORT)’s stock price gapped down before the market opened on Friday after Citizens Jmp lowered their price target on the stock from $48.00 to $42.00. The stock had previously closed at $25.33, but opened at $22.19. Citizens Jmp currently has a market outperform rating on the stock. Artivion shares last traded at $21.7750, with a volume of 167,974 shares.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Canaccord Genuity Group set a $30.00 price objective on Artivion in a research note on Friday. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Jefferies Financial Group initiated coverage on shares of Artivion in a research note on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.57.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Andrew Green sold 11,480 shares of Artivion stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president directly owned 40,160 shares of the company’s stock, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean Holloway sold 977 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. Corporate insiders own 6.30% of the company’s stock.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analyst estimates of about $121 million. Artivion also projected 2026 revenue of $484 million to $492 million, signaling continued growth. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company is preparing to launch its NEXUS aortic product in January 2027, a potential growth catalyst as it expands its product portfolio. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Profitability was weaker: Artivion reported a GAAP net loss of $7.9 million, while adjusted EPS of $0.08 fell short of Zacks’ $0.11 consensus and compared with $0.16 a year earlier. Adjusted EBITDA declined 8% to $22.5 million, which may temper the positive revenue news. Artivion lags Q3 earnings estimates
• Negative Sentiment: Canaccord lowered its price target on AORT to $30, a sign of reduced analyst expectations that could add pressure despite the company’s revenue growth. Canaccord lowers Artivion price target

Institutional Trading of Artivion

A number of large investors have recently added to or reduced their stakes in AORT. Rockefeller Capital Management L.P. raised its position in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares during the period. Pinnacle Wealth Planning Services Inc. grew its position in shares of Artivion by 362.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,379 shares of the company’s stock valued at $31,000 after acquiring an additional 1,081 shares during the period. Versant Capital Management Inc grew its position in shares of Artivion by 38.0% during the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock valued at $48,000 after acquiring an additional 584 shares during the period. Fulcrum Asset Management LLP bought a new position in shares of Artivion during the 3rd quarter valued at approximately $49,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Artivion during the 2nd quarter worth approximately $103,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Stock Performance

The company’s 50 day moving average price is $23.67 and its 200-day moving average price is $29.09. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a market cap of $1.03 billion, a PE ratio of -301.21 and a beta of 1.31.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The business had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million. Equities research analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.